NCT01507038

Safety and Efficacy of YH14617 in Diabetes Mellitus

Phase II Clinical Trial to Investigate the Efficacy, Safety and Pharmacokinetics of YH14617 After Once Weekly or Biweekly Administration in Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (actual)
• Sponsor: Yuhan Corporation · Industry
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to assess the safety, efficacy and pharmacokinetic of YH14617 after once weekly or biweekly injection in patients with type 2 Diabetes Mellitus to investigate the optimal recommended dosage. Study period is 20 weeks including 12 weeks of treatment period and 8weeks of follow-up period without treatment.

Conditions

• Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	YH14617	1mg once weekly
DRUG	YH14617	1.6mg once weekly
DRUG	YH14617	2mg once biweekly
DRUG	Placebo	Once weekly

Timeline

• Start date: 2011-12-01
• Primary completion: 2015-01-01
• Completion: 2015-02-01
• First posted: 2012-01-10
• Last updated: 2015-02-18

Locations

1 site across 1 country: South Korea